Regeneron, Sanofi report sarilumab data

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) reported data from two Phase IIb trials of autoimmune candidate sarilumab, a human mAb against IL-6 receptor.

Data from Part A of the MOBILITY trial in 306 patients with active rheumatoid arthritis (RA) showed that sarilumab plus methotrexate met the primary endpoint of a significantly greater proportion of patients achieving an ACR20 response at week 12 vs. placebo plus methotrexate (72% vs. 46.2%, p=0.02). ...